Scripps Research scientists have solved a major problem in chemistry and drug development by using droplet-sized ‘miniecosystems’ to quickly see if a molecule can function as a potential therapeutic.
"This new method should allow us to explore a large ‘chemical space’ that had been essentially off-limits."
A new study by Scripps Research, published today in Nature Communications, suggests scientists could build better drugs by learning from bacteria-derived molecules called thiocarboxylic acids.
Dubbed “T-cell engaging bi-specific antibodies,” these cancer combatants attack malignant cells but leave healthy cells untouched.
The new tool opens the possibility of creating drugs that can be taken conveniently as pills to correct genetic diseases.
Gilead Sciences’ Chairman of the Board of Directors, John C. Martin, PhD, has joined the Board of Directors at The Scripps Research Institute.
Former film executive Sherry Lansing, who led Paramount and Fox motion picture studios, has been named to the Board of Directors at The Scripps Research Institute.
The technique makes use of tiny, three-dimensional ball-like aggregates of cells called spheroids.
The new research opens the door to studying common brain conditions such as autism, schizophrenia, addiction and Alzheimer’s disease under reproducible conditions in a dish.
Floyd Romesberg, PhD, professor at The Scripps Research Institute, has won the 2018 Royal Society of Chemistry (RSC) Bioorganic Chemistry Award for his ground-breaking contributions to the expansion of the genetic alphabet.
Researchers take a closer look at drug candidate for a devastating genetic illness.
Working with mobile technology and bioinformatics companies, STSI will lead integration of mobile apps and digital medical devices into the program to collect and analyze an unprecedented range and depth of health data.
The research points to a possible new role for proteins in sensory processing in some people with autism spectrum disorder.
With the new funding from the Gates Foundation, the Scripps Research team will expand their studies of neutralizing antibodies.
The Scripps Translational Science Institute (STSI) has received over $34 million in renewed funding from the National Institutes of Health’s National Center for Advancing Translational Sciences (NCATS) to advance medical research and clinical care through genomic and digital technologies.
Scientists at The Scripps Research Institute are launching a pair of studies on genetic factors behind oxycodone and cocaine addiction and treatment.
Scientists at The Scripps Research Institute have identified a protein, called GPR68, that senses blood flow and tells small blood vessels called arterioles when to dilate.
This new insight may allow researchers to design drugs that improve immune responses to vaccines.
The researchers will investigate how to design antibodies to deliver drugs to fight chronic lymphocytic leukemia.
“As researchers, they take risks without knowing the answers...I really admire it.”
RSS
Medicine keyboard_arrow_right
Sciencekeyboard_arrow_right
Life keyboard_arrow_right
Business keyboard_arrow_right
Journal News keyboard_arrow_right
By Location keyboard_arrow_right
Meetings, Grants, and Events keyboard_arrow_right